|
시장보고서
상품코드
1831636
인간 마이크로바이옴 치료제 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 제품별, 치료 영역별, 적응증별, 접근법별, 지역별 예측(2025-2034년)Human Microbiome Therapeutics Market Size, Share, Trends, Industry Analysis Report By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), By Therapeutic Area, By Indication, By Approach, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최근 조사에 따르면, 인간 마이크로바이옴 치료제 시장 규모는 2034년까지 78억 9,000만 달러에 이를 것으로 예측됩니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.
인간 마이크로바이옴 치료제는 인간 마이크로바이옴(인체의 체내 및 체내에 서식하는 박테리아, 바이러스, 곰팡이, 고세균을 포함한 미생물의 다양한 공동체)의 조성 및 활성을 표적으로 하고, 회복 또는 수정하도록 설계된 치료군의 집합을 의미합니다. 이러한 치료제는 마이크로바이옴의 유익한 특성을 활용하여 다양한 질병을 예방, 치료 및 관리하는 것을 목표로 합니다. 이러한 치료제는 살아있는 생수처리 제품, 미생물 컨소시엄, 유전적으로 조작된 미생물, 프리바이오틱스, 포스트바이오틱스 등을 사용합니다. 인간 마이크로바이옴 치료제의 사용은 여러 치료 분야에 걸쳐 있습니다. 소화기내과에서는 클로스트리디오이데스 디피실 감염, 염증성 장 질환(IBD), 과민성 장 증후군(IBS) 등의 치료에 사용됩니다. 종양학에서는 면역 기능에 영향을 미치는 장내 박테리아를 조절하여 면역 요법에 대한 반응을 높일 수 있습니다.
비만이나 2형 당뇨병 등의 대사 질환, 자폐증 스펙트럼 장애나 파킨슨병 등의 신경 질환, 습진이나 여드름 등의 피부 질환에 대해서도 연구가 진행되고 있습니다. 또한 미생물 기반 개입은 알레르기 예방과 세균성 질염과 같은 여성의 건강 문제에 대해서도 연구되고 있습니다. 이러한 치료제는 경구 캡슐, 영양 보충제, 분변 미생물 이식(FMT) 또는 국소 제형을 통해 투여될 수 있습니다. 마이크로바이옴 시퀀싱, 합성 생물학, 맞춤형 의료의 발전으로 이 분야는 빠르게 발전하고 있습니다.
인간 마이크로바이옴 치료제 시장 보고서 하이라이트
제품별로 프로바이오틱스 분야는 위장장애 관리, 면역건강 강화, 장내 세균총 균형의 회복에 널리 사용되고 있기 때문에 2024년에 큰 매출 점유율을 차지했습니다.
용도별로는 과민성 장 증후군, 염증성 장질환, 클로스트리디오이데스디피실 감염증, 항생제 관련 설사증 등 질병의 세계적인 유병률이 높기 때문에 소화기 및 위장장애가 2024년 최대의 수익 점유율을 차지했습니다.
제조면에서 재발률 증가, 항생제 내성 증가, 종래의 항균제 치료를 대체하는 효과적인 치료법의 긴급한 필요성으로부터, 클로스트리듐 디피실 감염증 분야가 2024년의 수익 점유율을 독점했습니다.
북미의 인간 마이크로바이옴 치료제 시장은 2024년 세계 수익 점유율의 48.15%를 차지했습니다. 이 이점은 비만, 당뇨병, 염증성 장 질환(IBD)과 같은 만성 질환 증가 때문입니다.
아시아태평양의 산업은 의료 의식 증가와 가처분 소득 증가로 향후 몇 년 동안 가장 빠른 속도로 성장할 것으로 예측됩니다.
인간 마이크로바이옴 치료제 세계 시장에서 주요 기업으로는 Enterome SA, Ferring Pharmaceuticals, Finch Therapeutics Group Inc., Locus Biosciences Inc., MaaT Pharma, Microbiotica Ltd., Osel Inc., Seres Therapeutics Inc., Synlogic Inc., Vedanta Biosciences 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 인간 마이크로바이옴 치료제 시장 인사이트
- 시장 현황
- 인간 마이크로바이옴 치료제 시장 역학
- 성장 촉진요인과 기회
- 만성 질환의 높은 유병률
- 맞춤형 의료에 대한 주목의 고조
- 억제요인과 과제
- 확고한 임상 데이터와 인식의 부족
- 성장 촉진요인과 기회
- PESTEL 분석
- 인간 마이크로바이옴 치료제 시장 동향
- 밸류체인 분석
제5장 세계의 인간 마이크로바이옴 치료제 시장 : 제품별
- 주요 조사 결과
- 소개
- 프로바이오틱스
- 프리바이오틱스
- 의료용 식품
- 처방약
제6장 세계의 인간 마이크로바이옴 치료제 시장 : 치료 영역별
- 주요 조사 결과
- 소개
- 자가면역질환
- 치과 질환
- 소화기계 및 위장계의 질환
- 피부질환
- 감염증
- 대사 장애
- 종양학
- 기타
제7장 세계의 인간 마이크로바이옴 치료제 시장 : 적응증별
- 주요 조사 결과
- 소개
- 심상성 여드름
- 아토피 피부염
- 클로스트리듐 디피실 감염증
- 대장암
- 당뇨병
- 염증성 장질환(IBD)
- 유당 불내증
- 폐암
- 유당 불내증
- 비알코올성 지방간염(NASH)
- 비만
- 셀리악병
제8장 세계의 인간 마이크로바이옴 치료제 시장 : 접근법별
- 주요 조사 결과
- 소개
- 저분자 치료
- 단일 균주의 전체 세균
- 미생물 컨소시엄
- 유전자 변형 단일균주
- Phage Cocktail
- 미생물 생태계
제9장 세계의 인간 마이크로바이옴 치료제 시장 : 지역별
- 주요 조사 결과
- 소개
- 인간 마이크로바이옴 치료제 시장 평가:지역, 2020-2034년
- 북미
- 북미 : 제품별, 2020-2034년
- 북미 : 치료 영역별, 2020-2034년
- 북미 : 적응증별, 2020-2034년
- 북미 : 어프로치별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 제품별, 2020-2034년
- 유럽 : 치료 영역별, 2020-2034년
- 유럽 : 적응증별, 2020-2034년
- 유럽 : 어프로치별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품별, 2020-2034년
- 아시아태평양 : 치료 영역별, 2020-2034년
- 아시아태평양 : 적응증별, 2020-2034년
- 아시아태평양 : 접근법별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품별, 2020-2034년
- 중동 및 아프리카 : 치료 영역별, 2020-2034년
- 중동 및 아프리카 : 적응증별, 2020-2034년
- 중동 및 아프리카 : 어프로치별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품별, 2020-2034년
- 라틴아메리카 : 치료 영역별, 2020-2034년
- 라틴아메리카 : 적응증별, 2020-2034년
- 라틴아메리카 : 어프로치별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 프로파일
- Enterome Sa
- Ferring Pharmaceuticals
- Finch Therapeutics Group Inc.
- Locus Biosciences Inc.
- Maat Pharma
- Microbiotica Ltd
- Osel Inc.
- Seres Therapeutics Inc.
- Synlogic Inc.
- Vedanta Biosciences
The human microbiome therapeutics market size is expected to reach USD 7.89 billion by 2034, according to a new study by Polaris Market Research. The report "Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), By Therapeutic Area, By Indication, By Approach, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Human microbiome therapeutics refers to a class of medical treatments designed to target, restore, or modify the composition and activity of the human microbiome, the diverse community of microorganisms, including bacteria, viruses, fungi, and archaea, that live in and on the human body. These therapeutics aim to harness the beneficial properties of the microbiome to prevent, treat, or manage various diseases. They may involve the use of live biotherapeutic products, microbial consortia, genetically engineered microbes, prebiotics, or postbiotics. The usage of human microbiome therapeutics spans multiple therapeutic areas. In gastroenterology, they are used to treat conditions such as Clostridioides difficile infections, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). In oncology, they can enhance responses to immunotherapy by modulating gut bacteria that influence immune function.
They are being explored for metabolic disorders such as obesity and type 2 diabetes, neurological conditions like autism spectrum disorder and Parkinson's disease, and skin disorders including eczema and acne. Additionally, microbiome-based interventions are being investigated for allergy prevention and women's health issues, such as bacterial vaginosis. These therapeutics can be administered through oral capsules, dietary supplements, fecal microbiota transplantation (FMT), or topical formulations. The field is rapidly evolving due to advances in microbiome sequencing, synthetic biology, and personalized medicine.
Human Microbiome Therapeutics Market Report Highlights
In terms of product, the probiotics segment accounted for a major revenue share in 2024 due to their widespread use in managing gastrointestinal disorders, enhancing immune health, and restoring gut microbiota balance.
Based on application, the digestive and gastrointestinal disorders held the largest revenue share in 2024 due to high global prevalence of conditions such as irritable bowel syndrome, inflammatory bowel disease, Clostridioides difficile infection, and antibiotic-associated diarrhea.
In terms of manufacturing, the clostridium difficile infection segment dominated the revenue share in 2024 due to high recurrence rates, growing antibiotic resistance, and the urgent need for effective alternatives to conventional antimicrobial therapies.
North America human microbiome therapeutics market accounted for 48.15% of global revenue share in 2024. This dominance is attributed to the rising incidences of chronic diseases such as obesity, diabetes, and inflammatory bowel disease (IBD).
The industry in Asia Pacific is projected to grow at the fastest pace in the coming years, owing to increasing healthcare awareness and rising disposable incomes.
A few key players in the global human microbiome therapeutics market include Enterome SA, Ferring Pharmaceuticals, Finch Therapeutics Group Inc., Locus Biosciences Inc., MaaT Pharma, Microbiotica Ltd, Osel Inc., Seres Therapeutics Inc., Synlogic Inc., and Vedanta Biosciences.
Polaris Market Research has segmented the global human microbiome therapeutics market report on the basis of product, therapeutic area, indication, approach, and region:
By Product Outlook (Revenue, USD Billion, 2020-2034)
Probiotics
Prebiotics
Medical Foods
Prescription Drugs
By Therapeutic Area Outlook (Revenue, USD Billion, 2020-2034)
Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others
By Indication Outlook (Revenue, USD Billion, 2020-2034)
Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Diabetes
Inflammatory Bowel Disease (IBD)
Lactose Intolerance
Lung Cancer
Non-alcoholic steatohepatitis (NASH)
Obesity
Coeliac Disease
By Approach Outlook (Revenue, USD Billion, 2020-2034)
Small Molecule Therapies
Single Strain Whole Bacteria
Microbial Consortia
Genetically Modified Single Strain Bacteria
Phage Cocktail
Microbial Ecosystems
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source
4. Global Human Microbiome Therapeutics Market Insights
- 4.1. Human Microbiome Therapeutics Market - Market Snapshot
- 4.2. Human Microbiome Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. High Prevalence of Chronic Diseases
- 4.2.1.2. Growing Focus on Personalized Medicine
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of Robust Clinical Data and Awareness
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Human Microbiome Therapeutics Market Trends
- 4.6. Value Chain Analysis
5. Global Human Microbiome Therapeutics Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 5.3. Probiotics
- 5.3.1. Global Human Microbiome Therapeutics Market, by Probiotics, by Region, 2020-2034 (USD Billion)
- 5.4. Prebiotics
- 5.4.1. Global Human Microbiome Therapeutics Market, by Prebiotics, by Region, 2020-2034 (USD Billion)
- 5.5. Medical Foods
- 5.5.1. Global Human Microbiome Therapeutics Market, by Medical Foods, by Region, 2020-2034 (USD Billion)
- 5.6. Prescription Drugs
- 5.6.1. Global Human Microbiome Therapeutics Market, by Prescription Drugs, by Region, 2020-2034 (USD Billion)
6. Global Human Microbiome Therapeutics Market, by Therapeutic Area
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 6.3. Autoimmune Disorders
- 6.3.1. Global Human Microbiome Therapeutics Market, by Autoimmune Disorders, by Region, 2020-2034 (USD Billion)
- 6.4. Dental Disorders
- 6.4.1. Global Human Microbiome Therapeutics Market, by Dental Disorders, by Region, 2020-2034 (USD Billion)
- 6.5. Digestive and Gastrointestinal Disorders
- 6.5.1. Global Human Microbiome Therapeutics Market, by Digestive and Gastrointestinal Disorders, by Region, 2020-2034 (USD Billion)
- 6.6. Dermatological Disorders
- 6.6.1. Global Human Microbiome Therapeutics Market, by Dermatological Disorders, by Region, 2020-2034 (USD Billion)
- 6.7. Infectious Disease
- 6.7.1. Global Human Microbiome Therapeutics Market, by Infectious Disease, by Region, 2020-2034 (USD Billion)
- 6.8. Metabolic Disorders
- 6.8.1. Global Human Microbiome Therapeutics Market, by Metabolic Disorders, by Region, 2020-2034 (USD Billion)
- 6.9. Oncology
- 6.9.1. Global Human Microbiome Therapeutics Market, by Oncology, by Region, 2020-2034 (USD Billion)
- 6.10. Others
- 6.10.1. Global Human Microbiome Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Human Microbiome Therapeutics Market, by Indication
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 7.3. Acne Vulgaris
- 7.3.1. Global Human Microbiome Therapeutics Market, by Acne Vulgaris, by Region, 2020-2034 (USD Billion)
- 7.4. Atopic Dermatitis
- 7.4.1. Global Human Microbiome Therapeutics Market, by Atopic Dermatitis, by Region, 2020-2034 (USD Billion)
- 7.5. Clostridium difficile Infection
- 7.5.1. Global Human Microbiome Therapeutics Market, by Clostridium difficile Infection, by Region, 2020-2034 (USD Billion)
- 7.6. Colorectal Cancer
- 7.6.1. Global Human Microbiome Therapeutics Market, by Colorectal Cancer, by Region, 2020-2034 (USD Billion)
- 7.7. Diabetes
- 7.7.1. Global Human Microbiome Therapeutics Market, by Diabetes, by Region, 2020-2034 (USD Billion)
- 7.8. Inflammatory Bowel Disease (IBD)
- 7.8.1. Global Human Microbiome Therapeutics Market, by Inflammatory Bowel Disease (IBD), by Region, 2020-2034 (USD Billion)
- 7.9. Lactose Intolerance
- 7.9.1. Global Human Microbiome Therapeutics Market, by Lactose Intolerance, by Region, 2020-2034 (USD Billion)
- 7.10. Lung Cancer
- 7.10.1. Global Human Microbiome Therapeutics Market, by Lung Cancer, by Region, 2020-2034 (USD Billion)
- 7.11. Lactose Intolerance
- 7.11.1. Global Human Microbiome Therapeutics Market, by Lactose Intolerance, by Region, 2020-2034 (USD Billion)
- 7.12. Non-alcoholic steatohepatitis (NASH)
- 7.12.1. Global Human Microbiome Therapeutics Market, by Non-alcoholic steatohepatitis (NASH), by Region, 2020-2034 (USD Billion)
- 7.13. Obesity
- 7.13.1. Global Human Microbiome Therapeutics Market, by Obesity, by Region, 2020-2034 (USD Billion)
- 7.14. Coeliac Disease
- 7.14.1. Global Human Microbiome Therapeutics Market, by Coeliac Disease, by Region, 2020-2034 (USD Billion)
8. Global Human Microbiome Therapeutics Market, by Approach
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 8.3. Small Molecule Therapies
- 8.3.1. Global Human Microbiome Therapeutics Market, by Small Molecule Therapies, by Region, 2020-2034 (USD Billion)
- 8.4. Single Strain Whole Bacteria
- 8.4.1. Global Human Microbiome Therapeutics Market, by Single Strain Whole Bacteria, by Region, 2020-2034 (USD Billion)
- 8.5. Microbial Consortia
- 8.5.1. Global Human Microbiome Therapeutics Market, by Microbial Consortia, by Region, 2020-2034 (USD Billion)
- 8.6. Genetically Modified Single Strain Bacteria
- 8.6.1. Global Human Microbiome Therapeutics Market, by Genetically Modified Single Strain Bacteria, by Region, 2020-2034 (USD Billion)
- 8.7. Phage Cocktail
- 8.7.1. Global Human Microbiome Therapeutics Market, by Phage Cocktail, by Region, 2020-2034 (USD Billion)
- 8.8. Microbial Ecosystems
- 8.8.1. Global Human Microbiome Therapeutics Market, by Microbial Ecosystems, by Region, 2020-2034 (USD Billion)
9. Global Human Microbiome Therapeutics Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Human Microbiome Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Human Microbiome Therapeutics Market - North America
- 9.3.1. North America: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.3.2. North America: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.3.3. North America: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.3.4. North America: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.3.5. Human Microbiome Therapeutics Market - US
- 9.3.5.1. US: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.3.5.2. US: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.3.5.3. US: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.3.5.4. US: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.3.6. Human Microbiome Therapeutics Market - Canada
- 9.3.6.1. Canada: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4. Human Microbiome Therapeutics Market - Europe
- 9.4.1. Europe: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.2. Europe: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.3. Europe: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.4. Europe: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.5. Human Microbiome Therapeutics Market - UK
- 9.4.5.1. UK: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.6. Human Microbiome Therapeutics Market - France
- 9.4.6.1. France: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.6.2. France: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.6.3. France: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.6.4. France: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.7. Human Microbiome Therapeutics Market - Germany
- 9.4.7.1. Germany: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.8. Human Microbiome Therapeutics Market - Italy
- 9.4.8.1. Italy: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.9. Human Microbiome Therapeutics Market - Spain
- 9.4.9.1. Spain: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.10. Human Microbiome Therapeutics Market - Netherlands
- 9.4.10.1. Netherlands: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.11. Human Microbiome Therapeutics Market - Russia
- 9.4.11.1. Russia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.12. Human Microbiome Therapeutics Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5. Human Microbiome Therapeutics Market - Asia Pacific
- 9.5.1. Asia Pacific: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.5. Human Microbiome Therapeutics Market - China
- 9.5.5.1. China: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.5.2. China: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.5.3. China: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.5.4. China: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.6. Human Microbiome Therapeutics Market - India
- 9.5.6.1. India: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.6.2. India: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.6.3. India: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.6.4. India: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.7. Human Microbiome Therapeutics Market - Malaysia
- 9.5.7.1. Malaysia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.8. Human Microbiome Therapeutics Market - Japan
- 9.5.8.1. Japan: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.9. Human Microbiome Therapeutics Market - Indonesia
- 9.5.9.1. Indonesia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.10. Human Microbiome Therapeutics Market - South Korea
- 9.5.10.1. South Korea: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.11. Human Microbiome Therapeutics Market - Australia
- 9.5.11.1. Australia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.12. Human Microbiome Therapeutics Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6. Human Microbiome Therapeutics Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.5. Human Microbiome Therapeutics Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.6. Human Microbiome Therapeutics Market - UAE
- 9.6.6.1. UAE: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.7. Human Microbiome Therapeutics Market - Israel
- 9.6.7.1. Israel: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.8. Human Microbiome Therapeutics Market - South Africa
- 9.6.8.1. South Africa: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.9. Human Microbiome Therapeutics Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7. Human Microbiome Therapeutics Market - Latin America
- 9.7.1. Latin America: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.5. Human Microbiome Therapeutics Market - Mexico
- 9.7.5.1. Mexico: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.6. Human Microbiome Therapeutics Market - Brazil
- 9.7.6.1. Brazil: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.7. Human Microbiome Therapeutics Market - Argentina
- 9.7.7.1. Argentina: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.8. Human Microbiome Therapeutics Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Enterome Sa
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Ferring Pharmaceuticals
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Finch Therapeutics Group Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Locus Biosciences Inc.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Maat Pharma
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Microbiotica Ltd
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Osel Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Seres Therapeutics Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Synlogic Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Vedanta Biosciences
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
